Impact of Biomarkers on Pharmacokinetics and Pharmacodynamics of Ticagrelor
Latest Information Update: 05 Dec 2022
At a glance
- Drugs Ticagrelor (Primary)
- Indications Abdominal aortic aneurysm; Acute coronary syndromes; Angina pectoris; Cardiovascular disorders; Community-acquired pneumonia; Coronary artery disease; Sickle cell anaemia; Stroke
- Focus Adverse reactions; Pharmacogenomic
- 30 Apr 2022 Results (n=175) assessing effect of genetic polymorphism Including NUP153 and SVEP1 on the pharmacokinetics and pharmacodynamics of Ticagrelor of healthy Chinese subjects published in the Clinical Drug Investigation
- 19 Dec 2020 Planned End Date changed from 1 Dec 2020 to 1 Dec 2021.
- 19 Dec 2020 Planned primary completion date changed from 1 Oct 2020 to 1 Oct 2021.